ARTICLE | Clinical News
rNAPc2: Phase IIa data
November 21, 2005 8:00 AM UTC
In the double-blind, dose-escalation, U.S. and Canadian Phase IIa ANTHEM/TIMI 32 trial in 203 patients, rNAPc2 inhibited thrombin generation without increasing bleeding. Major and minor bleed rate wit...